LUCD Earnings Prediction
The chart below shows how LUCD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LUCD sees a -1.98% change in stock price 10 days leading up to the earnings, and a -6.00% change 10 days following the report. On the earnings day itself, the stock moves by +2.31%. This data can give you a slight idea of what to expect for the next quarter's release.
LUCD Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.17M
49.68%
20.08%
Gross Margin
-52.65%
-69.60%
-30.84%
Operating Margin
-997.78%
-29.79%
-12.99%
Net Margin
-1055.55%
-41.83%
-6.39%
EPS
-0.25
-26.47%
8.70%
No Data Available
LUCD Earnings Analysis
Lucid Diagnostics Inc. Common Stock Corporation (LUCD.O) Earnings Conference Call
Positive
Quarterly Revenue Milestone: 1. Record Quarterly Revenue: Lucid Diagnostics achieved a record revenue of $1.2 million in Q3 2024, marking a 20% increase quarter-on-quarter and a 50% increase compared to the same quarter last year.
Test Volume Surge: 2. Increased Test Volume: The company reported a test volume of 2,787 in Q3 2024, contributing to nearly $7 million in submitted claims, indicating strong demand for its EsoGuard test.
Cancer Detection Effectiveness: 3. High Sensitivity and Predictive Value: EsoGuard demonstrated an unprecedented sensitivity of 96% for cancer detection and a 99% negative predictive value, enhancing its value as a screening tool.
Cash Position Enhancement: 4. Robust Cash Position: As of September 30, 2024, Lucid Diagnostics had $14.5 million in cash, with plans to increase this by approximately $13.2 million through new convertible note agreements, extending its cash runway significantly.
Direct Contracting Expansion: 5. Expansion in Direct Contracting: The company is actively expanding its direct contracting initiatives, including successful events with firefighter unions, which are expected to drive contractually guaranteed revenue.
Negative
Test Volume Decline: 1. Declining Test Volume: Test volume decreased by 11% quarter-over-quarter, with 2,787 tests conducted in Q3 compared to 3,130 in Q2.
High Operational Costs: 2. High Operating Burn Rate: The quarterly burn rate was $10.4 million, consistent with the previous quarters, indicating ongoing high operational costs without significant revenue growth.
Cash Flow Concerns: 3. Limited Cash Runway: Cash at the end of Q3 was $14.5 million, with the company stating that its ability to fund operations beyond one year is largely dependent on revenue ramp-up, which remains uncertain.
Claims Denial Challenges: 4. Significant Denials in Claims: Of the adjudicated claims, 34% were denied as not medically necessary, and 23% were deemed non-covered, highlighting challenges in reimbursement.
Net Loss Per Share Stability: 5. Flat Net Loss Per Share: The non-GAAP net loss per share remained flat at $0.20, indicating no improvement in financial performance despite a slight increase in revenue.
LUCD FAQs
How does LUCD typically perform around its earnings report dates?
Is Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
LUCD Earning Call Sentiment
Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
LUCD.O
-14.39%Positive
The earnings call presents a positive outlook with strong year-over-year revenue growth, increased test volumes, and promising Medicare coverage efforts. Despite a high burn rate, the company expects increased cash from new agreements, indicating financial stability. The Q&A section highlights potential growth in concierge medicine and optimism for Medicare coverage, which could boost future revenue. The lack of a shareholder return plan is a minor concern. Overall, the sentiment is positive, with a strong focus on growth and strategic initiatives, likely leading to a 2% to 8% stock price increase.
